Vivus’ Qsiva Down But Not Out At EMA; Lundbeck Will Write Off Acrescent
This article was originally published in The Pink Sheet Daily
Executive Summary
Vivus’ decision to fight CHMP rejection of Qsiva is a worthy cause, but Lundbeck confirms that Acrescent’s not unexpected elimination is the end of the line for the Alzheimer’s drug combination.